RNA-Loaded Dendritic Cell Cancer Vaccine

Completed · Phase 1/Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.

Key facts

Study ID

NCT00087984

Run by

Argos Therapeutics

People needed

26

Starts

2004-01-01

Expected to finish

2008-09-01

Last updated by the study team

2013-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a new diagnosis of metastatic renal cell carcinoma;
• Must be at least 18 years or older;
• Have a scheduled unilateral nephrectomy;
• ECOG of 0 or 1;
• Free of brain metastases by CT or MRI;
• Normal renal function in contralateral kidney;
• Male or non-pregnant/non-lactating female on appropriate birth control methods while on study;
• Clinically acceptable screening results.
• No immunosuppressive therapy not limited to corticosteroids (including topical steroids or steroid containing inhalers), azathioprine cyclosporine two months prior to study entry;
• No active autoimmune disease

Where it is running

• University of California - Irvine — Orange, California, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Princess Margaret Hospital — Toronto, Ontario, Canada
• Jewish General Hospital — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.